Biocryst Pharmaceuticals Inc logo

BCRX

Biocryst Pharmaceuticals Inc

$12.26

Earnings Summary

Revenue
$75.83Mn
Net Profits
$-42.52Mn
Net Profit Margins
-56.08%

Highlights

Revenue:

Biocryst Pharmaceuticals Inc’s revenue jumped 84.97% since last year same period to $75.83Mn in the Q3 2022. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated 15.71% jump in its revenue since last 3-months.

Net Profits:

Biocryst Pharmaceuticals Inc’s net profit jumped 27.69% since last year same period to $-42.52Mn in the Q3 2022. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated 27.76% jump in its net profits since last 3-months.

Net Profit Margins:

Biocryst Pharmaceuticals Inc’s net profit margin jumped 60.91% since last year same period to -56.08% in the Q3 2022. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated 37.57% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Biocryst Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

Biocryst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a 9.07% jump from last quarter’s estimates.

EPS Estimate Current Year:

Biocryst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the Biocryst Pharmaceuticals Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.32
Return on Assets (ROA)
-0.24
Return on Equity (ROE)
-19.25

Highlights

Earning Per Share (EPS):

Biocryst Pharmaceuticals Inc’s earning per share (EPS) fell -33.33% since last year same period to -0.32 in the Q2 2022. This indicates that the Biocryst Pharmaceuticals Inc has generated -33.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biocryst Pharmaceuticals Inc’s return on assets (ROA) stands at -0.24.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biocryst Pharmaceuticals Inc’s return on equity (ROE) stands at -19.25.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2016-02-26
-0.26
-0.31
-19.23%
2015-11-06
-0.2
-0.2
0%

Company Information

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.

Organisation
Biocryst Pharmaceuticals Inc
Headquarters
4505 Emperor Boulevard, Durham, NC, United States, 27703
Employees
358
Industry
Health Technology
CEO
Jon Stonehouse

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*